<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="38d8b457-0c0f-45cb-bf90-965c5a01b198"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Methocarbamol Tablets, USP</content>
      <br/>
      <br/>
      <content styleCode="bold"> Rx only</content>
   </title>
   <effectiveTime value="20250423"/>
   <setId root="38d8b457-0c0f-45cb-bf90-965c5a01b198"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
            <name>Preferred Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                  <name>Preferred Pharmaceuticals Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                        <name>Preferred Pharmaceuticals Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68788-8867" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4e6c9052-3281-4bdf-b90f-c0255704ad0e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250423"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="68788-8867"/>
                        <name>Methocarbamol</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Methocarbamol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="59651-340" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="125OD7737X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Methocarbamol</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="125OD7737X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Methocarbamol</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68788-8867-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250423"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68788-8867-6" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250423"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68788-8867-9" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250423"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA213967" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250423"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>Biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">500;METT</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="28a90bc6-14b2-428b-ba32-61f701fe3ae1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Methocarbamol tablets, USP, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties. </paragraph>
                  <paragraph>The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C<sub>11</sub>H<sub>15</sub>NO<sub>5</sub> . Its molecular weight is 241.24. The structural formula is shown below.</paragraph>
                  <renderMultiMedia referencedObject="FC9B0662-E457-4094-A98D-03FF76A13B5B" ID="id421"/>
                  <paragraph>Methocarbamol is a white bulky powder, sparingly soluble in water and chloroform, soluble in alcohol only with heating and insoluble in benzene and <content styleCode="italics">n</content>-hexane.<br/>
                     <br/> Methocarbamol tablets USP, 500 mg are available as white in color, round, beveled edge, biconvex film-coated tablet containing 500 mg of methocarbamol USP for oral administration.<br/>
                     <br/> Methocarbamol tablets USP, 750 mg are available as white in color, biconvex capsule shaped film-coated tablet containing 750 mg of methocarbamol USP for oral administration.<br/>
                     <br/> Methocarbamol tablets USP, 500 mg and 750 mg contain the following inactive ingredients: corn starch, hypromellose, magnesium stearate, polyethylene glycol, povidone, sodium lauryl sulfate, sodium starch glycolate, talc and titanium dioxide.<br/>
                     <br/> FDA approved dissolution test specifications differ from USP for 500 mg.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <component>
                  <observationMedia ID="FC9B0662-E457-4094-A98D-03FF76A13B5B">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="methocarbamol-str.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="4fe3ccb0-9ef0-416a-8a0e-6db52de80d50"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>The mechanism of action of methocarbamol in humans has not been established, but may be due to general CNS depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmacokinetics</content>
                  </paragraph>
                  <paragraph>In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.</paragraph>
                  <paragraph>Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Special populations</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Elderly</content>
                  </paragraph>
                  <paragraph>The mean (± SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean [± SD] age, 69 [± 4] years) was slightly prolonged compared to a younger (mean [± SD] age, 53.3 [± 8.8] years), healthy population (1.5 [± 0.4] hours versus 1.1 [±0.27] hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41% to 43% versus 46% to 50%, respectively).</paragraph>
                  <paragraph>
                     <content styleCode="italics">Renally impaired</content>
                  </paragraph>
                  <paragraph>The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (± SD) elimination half-life in these two groups was similar: 1.2 (± 0.6) versus 1.1 (±0.3) hours, respectively.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hepatically impaired</content>
                  </paragraph>
                  <paragraph>In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean (± SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (± 1.62) hours and 1.11 (± 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40% to 45% compared to 46% to 50% in the normal subjects.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="63a196f2-8ef6-4135-b909-5353f90499d0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Methocarbamol tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="6986a7bb-4d00-46d0-98aa-03733433c8fb"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Methocarbamol tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="48035b5f-11a7-4b6b-9585-38b35005ed3f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34071-1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol should be cautioned about combined effects with alcohol and other CNS depressants.</paragraph>
                  <paragraph>Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see <content styleCode="bold">
                        <linkHtml href="#Section_6">PRECAUTIONS</linkHtml>, <linkHtml href="#Section_6.7">Pregnancy</linkHtml>
                     </content>).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Use in Activities Requiring Mental Alertness</content>
                  </paragraph>
                  <paragraph>Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="742c141d-7c70-403a-92fe-b19cfeb208ee"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42232-9" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20250423"/>
               <component>
                  <section ID="Section_6.2">
                     <id root="d6d1c09f-75be-458f-a761-53b90394b42f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.</paragraph>
                        <paragraph>Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.4">
                     <id root="0e546169-0496-4115-ab5c-4b7080f06320"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>See <content styleCode="bold">
                              <linkHtml href="#Section_5">WARNINGS</linkHtml>  </content>and <content styleCode="bold">
                              <linkHtml href="#Section_6">PRECAUTIONS</linkHtml>  </content>for interaction with CNS drugs and alcohol.</paragraph>
                        <paragraph>Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.5">
                     <id root="ec2a8da5-dfe0-4b2d-8a3d-48c42e56a6f8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34074-5" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.6">
                     <id root="cf793d16-be87-47af-885c-6f22604595ce"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.7">
                     <id root="fb0ba21c-db65-4004-9e08-bf3c187d66c5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Teratogenic Effects</content>
                        </paragraph>
                        <paragraph>Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol should be given to a pregnant woman only if clearly needed.</paragraph>
                        <paragraph>Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see <content styleCode="bold">
                              <linkHtml href="#Section_5">WARNINGS</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.9">
                     <id root="8356085d-14bd-4114-a8e7-8ee7d5eed015"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34080-2" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methocarbamol is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.10">
                     <id root="041ff46e-f5e4-4be3-b3ac-ac0405d586cb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of methocarbamol in pediatric patients below the age of 16 have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="6e0504be-1115-49f3-b5fd-8b180efb7f50"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Adverse reactions reported coincident with the administration of methocarbamol include: </paragraph>
                  <paragraph>
                     <content styleCode="italics">Body as a whole: </content>Anaphylactic reaction, angioneurotic edema, fever, headache </paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiovascular system: </content>Bradycardia, flushing, hypotension, syncope, thrombophlebitis </paragraph>
                  <paragraph>
                     <content styleCode="italics">Digestive system: </content>Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hemic and lymphatic system: </content>Leukopenia</paragraph>
                  <paragraph>
                     <content styleCode="italics">Immune system: </content>Hypersensitivity reactions<br/>
                     <br/>
                     <content styleCode="italics"> Nervous system: </content>Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo</paragraph>
                  <paragraph>
                     <content styleCode="italics">Skin and special senses: </content>Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria</paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="Section_9">
               <id root="bbd0c69d-b8f0-47eb-b4c8-c8fdc7914550"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.</paragraph>
                  <paragraph>In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Treatment</content>
                  </paragraph>
                  <paragraph>Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="b34af344-22ce-47ce-9717-149ae7b30c08"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Methocarbamol tablets, 500 mg - Adults:</paragraph>
                  <paragraph>Initial dosage: 3 tablets 4 times daily.</paragraph>
                  <paragraph>Maintenance dosage: 2 tablets 4 times daily.</paragraph>
                  <paragraph>Methocarbamol tablets: 750 mg - Adults:</paragraph>
                  <paragraph>Initial dosage: 2 tablets 4 times daily.</paragraph>
                  <paragraph>Maintenance dosage: 1 tablet q.4h. or 2 tablets 3 times daily.</paragraph>
                  <paragraph>Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered.) Thereafter, the dosage can usually be reduced to approximately 4 grams a day.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="1e152e3c-8fc5-4680-a725-2423c475b06a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Methocarbamol Tablets USP, 500 mg</content> are white in color, round, beveled edge, biconvex film-coated tablet debossed with “500” above the score line on one side and “METT” on the other side. They are supplied as follows:</paragraph>
                  <paragraph>                    Bottles of 30                         NDC 68788-8867-3</paragraph>
                  <paragraph>                    Bottles of 60                         NDC 68788-8867-6</paragraph>
                  <paragraph>                    Bottles of 90                         NDC 68788-8867-9</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at</content> 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].         </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense in tight container.</content>
                  </paragraph>
                  <paragraph>For more information, call Aurobindo Pharma USA, Inc.at 1-866-850-2876.</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Aurobindo Pharma USA, Inc.</content>
                     <br/>279 Princeton-Hightstown Road<br/>East Windsor, NJ 08520<br/>
                     <br/> Manufactured by:<br/>
                     <content styleCode="bold">Aurobindo Pharma Limited</content>
                     <br/>Hyderabad-500 032, India <br/>
                     <br/> Revised: 08/2022</paragraph>
                  <paragraph>
                     <content styleCode="bold">Repackaged By: Preferred Pharmaceuticals Inc.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="05a62234-841b-4352-a07b-462ca1b7529a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg </title>
               <text>
                  <paragraph>NDC 68788-8867<br/>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                     <br/>
                     <content styleCode="bold"> Methocarbamol</content>
                     <br/>
                     <content styleCode="bold"> Tablets, USP</content>
                     <br/>
                     <content styleCode="bold"> 500 mg</content>
                     <br/>
                     <br/>
                     <content styleCode="bold"> AUROBINDO                  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Repackaged By: Preferred Pharmaceuticals Inc.</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="CD189F50-0656-40AF-B009-8CC1E694F8C8" ID="id708"/>
                  <br/>
               </text>
               <effectiveTime value="20250423"/>
               <component>
                  <observationMedia ID="CD189F50-0656-40AF-B009-8CC1E694F8C8">
                     <text>Methocarbamol Tab USP 500mg </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="methocarbamol-fig1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>